Hefiya

Hefiya is a prescription medication that contains the active ingredient adalimumab, a biologic TNF‑α inhibitor administered by subcutaneous injection. Marketed in the European Union, Hefiya is supplied in a solution for self‑injection, though specific strength details are not publicly disclosed. It belongs to the immunosuppressant class and is used to reduce inflammation in several autoimmune disorders. The product is intended for adult patients under medical supervision.

Hefiya is indicated for the treatment of several chronic inflammatory and autoimmune conditions.

- Rheumatoid arthritis - Psoriatic arthritis - Ankylosing spondylitis - Inflammatory bowel disease (Crohn’s disease and ulcerative colitis) - Plaque psoriasis - Hidradenitis suppurativa

Adalimumab may cause a range of adverse effects, which are generally categorized as common or serious.

Common: - Injection‑site pain, redness, or swelling - Upper respiratory tract infections (e.g., sinusitis, nasopharyngitis) - Headache - Mild skin rash or itching

Serious: - Severe infections such as tuberculosis or opportunistic fungal infections - Malignancies, including lymphoma and skin cancers - Demyelinating disorders of the central nervous system - New or worsening heart failure

Before initiating Hefiya, clinicians should evaluate patients for conditions that could increase risk during therapy.

- Screen for latent tuberculosis and treat before starting therapy - Assess hepatitis B status and vaccinate if non‑immune - Review history of recurrent or chronic infections - Consider potential risks in pregnancy, lactation, and women of child‑bearing age - Monitor for signs of malignancy or demyelinating disease - Use caution in patients with moderate to severe congestive heart failure

Adalimumab can interact with other medicines, requiring careful management.

Avoid: - Concurrent use of live vaccines (e.g., yellow fever, BCG) - Other biologic agents that target TNF‑α or the immune system

Use with caution: - Immunosuppressants such as methotrexate, azathioprine, or cyclophosphamide - Systemic corticosteroids, especially at high doses - Vaccinations that are not live (e.g., influenza, pneumococcal) – timing should be coordinated - Scheduled surgeries or invasive dental procedures - Antiviral therapies for chronic hepatitis B